BIODESIX INC — Director's Dealing 2024

May 24, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIODESIX INC (BDSX)
CIK: 0001439725
Period of Report: 2024-05-21

Reporting Person: Kennedy Lawrence T. Jr (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-05-23	Common Stock	M	1739120	—	Acquired	12267873	Indirect
2024-05-23	Common Stock	M	2608720	—	Acquired	2775386	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-05-21	Restricted Stock Units	$	A	46686	Acquired		Common Stock (46686)	Direct
2024-05-21	Stock Options (Right to Buy)	$1.57	A	37050	Acquired	2034-05-20	Common Stock (37050)	Direct
2024-05-23	Series A Non-Voting Convertible Preferred Stock	$	M	43478	Disposed		Common Stock (1739120)	Indirect
2024-05-23	Series A Non-Voting Convertible Preferred Stock	$	M	65218	Disposed		Common Stock (2608720)	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	10304824	Indirect

Footnotes

F1: The Issuer's stockholders approved the conversion of shares of the Issuer's Series A Non-Voting Convertible Preferred Stock ("Preferred Stock") into shares of the Issuer's common stock ("Common Stock") at its 2024 annual meeting of stockholders held on May 21, 2024, after which each share of Preferred Stock automatically converted into 40 shares of Common Stock on May 23, 2024.

F2: Reported amount has been adjusted to reflect the September 18, 2023 transfer of 687,515 shares of Common Stock previously held by the Lair BDSX GRAT 2022-3.2 to the Lawrence T. Kennedy, Jr. Revocable Trust UAD 6/19/01 and the March 11, 2024 transfer of 34,526 shares of Common Stock previously held by the Lair BDSX GRAT 2022-3.2 to the Lawrence T. Kennedy, Jr. Revocable Trust UAD 6/19/01 (the "March 11, 2024 Transfer"), each of which transfer was exempt from Section 16 pursuant to Rule 16a-13 under the Exchange Act. The Lair BDSX GRAT 2022-3.2 ceased to beneficially own any shares of Common Stock following the March 11, 2024 Transfer.

F3: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of Common Stock.

F4: These RSUs will vest in full on March 31, 2025, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. In the event the Reporting Person's continued service on the Board terminates other than for cause, these RSUs will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period.

F5: Represents deferred RSUs. The shares of Common Stock underlying these RSUs will be issued to the Reporting Person following the Reporting Person's separation from service with the Issuer.

F6: This option will vest in full on March 31, 2025, generally subject to the Reporting Person's continued service with the Issuer. In the event the Reporting Person's continued service on the Board terminates other than for cause, this option will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period.